Vaxcyte, Inc.
PCVX
$54.58
-$1.63-2.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -766.63M | -657.20M | -547.50M | -509.63M | -463.93M |
| Total Depreciation and Amortization | 24.86M | 19.85M | 19.14M | 17.63M | 15.85M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 89.64M | 81.44M | 57.90M | 62.80M | 50.35M |
| Change in Net Operating Assets | -3.45M | 13.77M | 10.91M | -30.58M | -54.90M |
| Cash from Operations | -655.58M | -542.15M | -459.55M | -459.78M | -452.63M |
| Capital Expenditure | -56.97M | -78.58M | -104.61M | -133.84M | -119.16M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 494.33M | -156.36M | -1.17B | -1.30B | -1.89B |
| Cash from Investing | 437.35M | -234.94M | -1.27B | -1.43B | -2.01B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13.01M | 15.58M | 1.54B | 1.65B | 2.46B |
| Repurchase of Common Stock | -10.99M | -11.07M | -16.43M | -14.29M | -14.29M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | -1.98M | 0.00 |
| Cash from Financing | 2.01M | 4.51M | 1.52B | 1.63B | 2.45B |
| Foreign Exchange rate Adjustments | 2.44M | 3.61M | -2.25M | -4.46M | 426.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -213.77M | -768.96M | -211.71M | -264.45M | -9.36M |